Alivus Life Sciences (NSE:ALIVUS) 1-Year Sharpe Ratio: 0.36 (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
80 GF Score
Price ₹1,350.20
GF Value ₹1,044.92
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alivus Life Sciences 1-Year Sharpe Ratio?

Alivus Life Sciences NSE:ALIVUS -0.59% 80 1-Year Sharpe Ratio is 0.36 as of Aug. 29, 2026. GuruFocus rates NSE:ALIVUS with a GF Score™ of 80/100 and a GF Value™ of ₹1,044.92 (Modestly Overvalued). The stock has 7 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-29), Alivus Life Sciences's 1-Year Sharpe Ratio is 0.36.

Alivus Life Sciences  (NSE:ALIVUS) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Alivus Life Sciences 1-Year Sharpe Ratio Related Terms

NSE:ALIVUS vs ZTS: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alivus Life Sciences 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's 1-Year Sharpe Ratio falls into.


NSE:ALIVUS
80GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 0.36 mean?
Alivus Life Sciences (NSE:ALIVUS) has a 1-Year Sharpe Ratio of 0.36 as of Aug. 29, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Alivus Life Sciences and its competitors.
Is Alivus Life Sciences' 1-Year Sharpe Ratio too high?
Alivus Life Sciences' current 1-Year Sharpe Ratio is 0.36. Overall, Alivus Life Sciences has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' 1-Year Sharpe Ratio compare to ZTS?
Alivus Life Sciences' 1-Year Sharpe Ratio of 0.36 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Alivus Life Sciences and its competitors. Alivus Life Sciences's current 1-Year Sharpe Ratio is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,044.92, compared to a current price of ₹1,350.20 — trading 29.2% above its estimated fair value. The current 1-Year Sharpe Ratio is 0.36. Alivus Life Sciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current 1-Year Sharpe Ratio is 0.36 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,350.20 is trading 29.2% above its estimated GF Value™ of ₹1,044.92. GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.

Key valuation signals for NSE:ALIVUS:

  • 1-Year Sharpe Ratio: 0.36
  • GF Value™: ₹1,044.92 vs. price of ₹1,350.20 (29.2% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
80GF Score

Get the complete analysis for NSE:ALIVUS

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,350.20
Price
₹1,044.92
GF Value